Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $24.50

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $24.50.

ATXS has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, January 21st. Lifesci Capital cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Finally, Cantor Fitzgerald lowered Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Wednesday, November 12th.

Astria Therapeutics Price Performance

NASDAQ:ATXS opened at $12.58 on Tuesday. The company has a fifty day moving average price of $12.71 and a 200 day moving average price of $10.81. Astria Therapeutics has a one year low of $3.56 and a one year high of $13.29. The stock has a market cap of $718.13 million, a P/E ratio of -5.88 and a beta of 0.01.

Institutional Trading of Astria Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Astria Therapeutics in the fourth quarter worth about $25,000. Strs Ohio bought a new stake in shares of Astria Therapeutics during the fourth quarter valued at approximately $45,000. Russell Investments Group Ltd. increased its holdings in shares of Astria Therapeutics by 10,311.8% in the third quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 3,506 shares in the last quarter. Farther Finance Advisors LLC raised its position in Astria Therapeutics by 22.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,693 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,222 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Astria Therapeutics in the 4th quarter worth approximately $88,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.